Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Warrants

Warrants

9 Months Ended

Sep. 30, 2019

On January 14, 2019, we issued 31,111 warrants to purchase common stock at $7.43 per share. The warrants are immediately exercisable and expire on January 9, 2024. On January 31, 2019 we issued 35,507 warrants to purchase common stock at $7.59 per share. These warrants are immediately exercisable and expire on January 26, 2024. All of these warrants were issued in conjunction with the 2019 Offerings.

During the three and nine months ended September 30, 2019, 122,500 warrants issued as part of a public offering of the Company's common stock and warrants in December 2017 (the "2017 Offering") expired unexercised.

The following table summarizes the warrant activity for the nine months ended September 30, 2019 (in thousands, except exercise price):



Issued With / For	Exercise Price			Warrants Outstanding January 1, 2019	2019 Warrants Issued	2019 Warrants Expired		Warrants Outstanding September 30, 2019
Non-Derivative Warrants:
Financing	$	300.00		8	—	—		8
Financing	450.00			9	—	—		9
2015 Offering	150.00			115	—	—		115
2017 Debt	27.60			15	—	—		15
2019 Offering	7.43			—	31	—		31
2019 Offering	7.59			—	35	—		35
Total non-derivative warrants	115.54		B	147	66	—		213
Derivative Warrants:
2016 Offerings	67.50		A	66	—	—		66
2017 Offering	70.50		A	117	—	(117	)	—
2017 Offering	75.00		A	6	—	(6	)	—
Total derivative warrants	67.50		B	189	—	(123	)	66
Total	$	104.18	B	336	66	(123	)	279


A	These warrants are subject to fair value accounting and contain a contingent net cash settlement feature. See Note 12.


B	Weighted-average exercise prices are as of September 30, 2019.